Genetic polymorphism of CYP17 and breast cancer risk in Korean women

Experimental and Molecular Medicine

Volumn 37, Issue 1, 2005, Pages 11-17

  Shin, Myung Hee ^a   Lee, Kyoung Mu ^b   Yang, Jung Hyun ^c   Nam, Seok Jin ^c   Kim, Jong Won ^a   Yoo, Keun Young ^b   Park, Sue Kyung ^d   Noh, Dong Young ^b   Ahn, Sei Hyun ^e   Kim, Bongcheol ^f   Kang, Daehee ^b  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Department of Surgery ^*  (South Korea)

^d Konkuk University School of Medicine   (South Korea)

^e University of Ulsan College of Medicine   (South Korea)

^f Seoul National University   (South Korea)

Author keywords

Breast neoplasms; Estrogens; Genetic polymorphism; Genotype; Steroid hydroxylases

Indexed keywords

DNA; ESTROGEN; STEROID MONOOXYGENASE;

5' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; RISK FACTOR; SOUTH KOREA;

EID: 20144370293     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2005.2     Document Type: Article

References (27)

1. Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors. Breast Cancer Res 2003;5:R45-51
2. Carey AH, Waterworth D, Patel K, White D, Little J, Novelli P, Franks S, Williamson R. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3: 1873-6
3. Cleary MP, Maihle NJ. The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med 1997;216: 28-43
4. Cui JS, Spurdle AB, Southey MC, Dite GS, Venter DJ, McCredie MRE, Giles GG, Chenevix-Trench G, Hopper JL. Regressive logistic and proportional hazards disease models for within-family analyses of measured genotypes, with application to a CYP17 polymorphism and breast cancer. Genet Epidemiol 2003;24:161-72
5. Dunning AM, Healey CS, Pharoah PD, Foster NA, Lipscombe JM, Redman KL, Easton DF, Day NE, Ponder BA. No association between a polymorphism in the steroid metabolism gene CYP17 and risk of breast cancer. Br J Cancer 1998;77:2045-7
6. Dunning AM, Healey CS, Pharoah PDP, Tear MD, Ponder BAJ, Easton DFA. Systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev 1999;8:843-54
7. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 1994;57:1063-5
8. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-7
9. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer. Cancer Res 1999;59: 1015-20
10. Hamajima N, Iwata H, Obata Y, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, Ohashi K, Tajima K. No association of the 5′ promoter region polymorphism of CYP17 with breast cancer risk in Japan. Jpn J Cancer Res 2000;91:880-5
11. Hankinson SE, Willett WC, Manson JE, Colditz GA, Hunter DJ, Spiegelman D, Barbieri RL, Speizer FE. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998;90:1292-9
12. Hefler LA, Tempfer CB, Grimm C, Lebrecht A, Ulbrich E, Heinze G, Leodolter S, Schneeberger C, Mueller MWW, Muendlein A, Koelbl H. Estrogen-metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women. Cancer 2004;101: 264-9
13. Helzlsouer KH, Huang HY, Strickland PT, Hoffman S, Alberg AH, Comstock GW, Bell DA. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 1998;7:945-9
14. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-5
15. Kristensen VN, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borrensen-Dale A. CYP17 and breast cancer risk: The polymorphism in the 5′ flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59:2825-8
16. Kuligina ES, Togo AV, Suspitsin EN, Grigoriev MY, Pozharisskiy KM, Changunava OL, Berstein LM, Theillet C, Hanson KP, Imyanitov EN. CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. Cancer Lett 2000;156:45-50
17. Lai J, Vesprini D, Chu W, Jernstrom H, Narod SA. CYP gene polymorphisms and early menarche. Mol Genet Metab 2001;74:449-57
18. Lee SA, Kang D, Nishio H, Lee MJ, Kim DH, Han W, Yoo KY, Ahn SH, Choe KJ, Hirvonen A, Non DY. Methylenetetrahydrofolate reductase polymorphism, diet, and breast cancer in Korean women. Exp Mol Med 2004;36:116-21
19. Miyoshi Y, Iwao K, Ikeda N, Egawa C, Noguchi S. Genetic polymorphism in CYP17 and breast cancer risk in Japanese women. Eur J Cancer 2000;36:2375-9
20. Miyoshi Y, Ando A, Ooka M, Shiba E, Taguchi T, Tamaki Y, Noguchi S. Association of CYP17 genetic polymorphism with intra-tumoral estradiol concentrations but not with CYP17 messenger RNA levels in breast cancer tissue. Caner Lett 2003;195:81-6
21. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A. Steroid metabolism gene CYP17 polymorphism and the development of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9:1343-8
22. Nedelcheva Kristensen V, Haraldsen EK, Anderson KB, Lonning PE, Erikstein B, Karesen R, Gabrielsen OS, Borresen-Dale AL. CYP17 and breast cancer risk: the polymorphism in the 5′-flanking area of the gene does not influence binding to Sp-1. Cancer Res 1999;59:2825-8
23. Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G. CYP17 promoter polymorphism and breast cancer in Australian women under age forty years. J Natl Cancer Inst 2000;92:1674-81
24. Tworoger SS, Chubak J, Aiello EJ, Ulrich CM, Atkinson C, Potter JD, Yasui Y, Stapleton PL, Lampe JW, Farin FM, Stanczyk FZ, McTiernan A. Association of CYP17, CYP19, CYP1B1, and COMT polymorphisms with serum and urinary sex hormone concentrations in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:94-101
25. Weston A, Pan CF, Bleiweiss IJ, Ksieski HB, Roy N, Maloney N, Wolff MS. CYP17 genotype and breast cancer risk. Cancer Epidemiol Biomarkers Prev 1998;7:941-4
26. Wu AH, Seow A, Arakawa K, van den berg D, Lee HP, Yu MC. HSD171B1 and CYP17 polymorphisms and breast cancer risk among Chinese women in Singapore. Int J Cancer 2003;104:450-7
27. Ye Z, Parry JM. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis. Mutagenesis 2002;17: 119-26